When, if at all, is it appropriate to re-challenge a patient with a EGFR inhibitor in metastatic RAS/BRAF WT colon cancer?  

Following the MD Anderson data presented several years ago by Parseghian et al., PMID 30462160 regarding successful rechallenge after the resistant RAS/EGFR clones decay from detection in the blood, I do utilize ctDNA profiling primarily at times of progression with the intent of rechallenging. Anec...

We have been encouraged by the CRICKET study, E-Rechallenge trial, and some other retrospective study data supporting the EGFRi rechallenge in patients with negative RAS/BRAF by ctDNA test. This has been used routinely in our clinic. Here is a nice review article that summarized the evidence we have...